Dishman Carbogen Amcis Limited (DCAL.NS) NSE
Currency In INR
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In INR
Sector
Healthcare
Industry
Biotechnology
Employees
1132
First IPO Date
April 22, 2004
| Name | Title | Pay | Year Born |
| Himani S. Dhotre | Chief Executive Officer of Projects & Operations | 0 | N/A |
| Deohooti Janmejay Vyas | Whole Time Director | 12M | 1951 |
| Lucie Framinet | Marketing Manager | 0 | N/A |
| Arpit Janmejay Vyas | Global MD & Director | 0 | 1986 |
| Dharmesh Desai | GM of Secretarial & Legal | 0 | N/A |
| Harshil R. Dalal | Global Chief Financial Officer | 0 | N/A |
| Paolo Armanino | Chief Operating Officer of Indian Operations | 0 | N/A |
| Shrima Gaurangbhai Dave | Compliance Officer & Company Secretary | 0 | N/A |
| Alan Fischer | Chief Technology Officer of CARBOGEN AMCIS | 0 | N/A |
| Martin Schneider | Chief Quality & Compliance Officer of CARBOGEN AMCIS | 0 | 1959 |
Established in 1983 and headquartered in Ahmedabad, India, Dishman Carbogen Amcis Limited provides specialized contract research and manufacturing solutions to the worldwide pharmaceutical sector. The company operates through two main business segments: Contract Research and Manufacturing Services (CR&MS), and Marketable Molecules. Beyond its core services, it manufactures and distributes an extensive portfolio of products, including bulk drugs, chemical intermediates, various phase transfer catalysts, quaternary ammonium compounds, phosphoranes, wittig reagents, vitamin D derivatives, and fine chemicals. Additionally, its offerings encompass personal care products like hand and body washes, sanitizers, and antiseptics, as well as a range of pharmaceutical and cosmetic formulations, including generic and highly potent active pharmaceutical ingredients. Dishman Carbogen Amcis Limited is a subsidiary of Adimans Technologies LLP.